Bal Pharma Limited (BALPHARMA.NS)
INR 120.5
(-0.08%)
INR 120.5
(-0.08%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.51 Billion INR | 0.66% |
| 2022 | 2.49 Billion INR | 23.48% |
| 2021 | 2.02 Billion INR | 8.2% |
| 2020 | 1.86 Billion INR | -3.28% |
| 2019 | 1.93 Billion INR | -4.0% |
| 2018 | 2.01 Billion INR | 4.94% |
| 2017 | 1.91 Billion INR | 12.59% |
| 2016 | 1.7 Billion INR | 8.88% |
| 2015 | 1.56 Billion INR | 43.8% |
| 2014 | 1.08 Billion INR | 3.82% |
| 2013 | 1.04 Billion INR | -0.5% |
| 2012 | 1.05 Billion INR | 4.07% |
| 2011 | 1.01 Billion INR | 2.0% |
| 2010 | 991.28 Million INR | 12.09% |
| 2009 | 884.39 Million INR | 4.91% |
| 2008 | 843.01 Million INR | 14.22% |
| 2007 | 738.08 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 2.51 Billion INR | 0.0% |
| 2023 Q2 | 2.66 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 2.51 Billion INR | 0.66% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 2.31 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 2.49 Billion INR | 23.48% |
| 2022 Q4 | 2.49 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 2.05 Billion INR | 0.0% |
| 2021 FY | 2.02 Billion INR | 8.2% |
| 2021 Q4 | 2.02 Billion INR | 0.0% |
| 2020 Q4 | 1.86 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 2.07 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 1.86 Billion INR | -3.28% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 1.93 Billion INR | -4.0% |
| 2019 Q2 | 1.89 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q4 | 1.93 Billion INR | 0.0% |
| 2018 Q4 | 2.01 Billion INR | 0.0% |
| 2018 FY | 2.01 Billion INR | 4.94% |
| 2017 FY | 1.91 Billion INR | 12.59% |
| 2017 Q4 | 1.91 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 FY | 1.7 Billion INR | 8.88% |
| 2016 Q4 | 1.7 Billion INR | 0.0% |
| 2016 Q2 | 1.54 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 1.56 Billion INR | 43.8% |
| 2015 Q4 | 1.56 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q2 | 1.36 Billion INR | 0.0% |
| 2014 Q2 | 1.04 Billion INR | 0.0% |
| 2014 FY | 1.08 Billion INR | 3.82% |
| 2014 Q4 | 1.08 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q2 | 1.15 Billion INR | 0.0% |
| 2013 Q4 | 1.04 Billion INR | 0.0% |
| 2013 FY | 1.04 Billion INR | -0.5% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2012 Q2 | 1.01 Billion INR | 0.0% |
| 2012 FY | 1.05 Billion INR | 4.07% |
| 2012 Q4 | 1.05 Billion INR | 0.0% |
| 2011 Q4 | 1.01 Billion INR | 0.0% |
| 2011 FY | 1.01 Billion INR | 2.0% |
| 2010 FY | 991.28 Million INR | 12.09% |
| 2009 FY | 884.39 Million INR | 4.91% |
| 2008 FY | 843.01 Million INR | 14.22% |
| 2007 FY | 738.08 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Sigachi Industries Limited | 2.53 Billion INR | 0.79% |
| Ind-Swift Limited | 13.45 Billion INR | 81.333% |
| Bajaj HealthCare Limited | 4.86 Billion INR | 48.409% |
| Sakar Healthcare Limited | 1.26 Billion INR | -98.79% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 98.35% |
| Innova Captab Limited | 4.89 Billion INR | 48.748% |
| Divi's Laboratories Limited | 18.99 Billion INR | 86.776% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | 31.407% |
| Morepen Laboratories Limited | 4.45 Billion INR | 43.691% |
| Mankind Pharma Limited | 23.87 Billion INR | 89.481% |
| Sequent Scientific Limited | 8.27 Billion INR | 69.65% |
| Wanbury Limited | 3.15 Billion INR | 20.416% |
| Laurus Labs Limited | 42.71 Billion INR | 94.121% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 77.614% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | 51.528% |
| Alembic Limited | 1.43 Billion INR | -75.356% |
| Hikal Limited | 12.99 Billion INR | 80.675% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 84.569% |
| Neuland Laboratories Limited | 5.49 Billion INR | 54.328% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 76.548% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 96.143% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 60.32% |
| Themis Medicare Limited | 1.88 Billion INR | -33.047% |
| RPG Life Sciences Limited | 1.38 Billion INR | -81.95% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 96.502% |
| Lupin Limited | 96.23 Billion INR | 97.391% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -220.388% |
| Wockhardt Limited | 39.87 Billion INR | 93.701% |
| Vaishali Pharma Limited | 371.16 Million INR | -576.597% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 69.563% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -746.231% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 95.902% |
| FDC Limited | 3.7 Billion INR | 32.296% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 97.652% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -290.021% |
| Eris Lifesciences Limited | 38.26 Billion INR | 93.438% |
| Venus Remedies Limited | 1.39 Billion INR | -80.304% |
| ZIM Laboratories Limited | 2.08 Billion INR | -20.69% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -19.083% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -1471.6% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | 28.364% |
| Shilpa Medicare Limited | 12.93 Billion INR | 80.582% |
| Albert David Limited | 1.15 Billion INR | -118.352% |
| Ajanta Pharma Limited | 10.71 Billion INR | 76.553% |
| Hester Biosciences Limited | 3.59 Billion INR | 30.14% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -23.451% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | 82.179% |
| Gufic Biosciences Limited | 5.59 Billion INR | 55.154% |
| Windlas Biotech Limited | 1.76 Billion INR | -42.468% |
| Procter & Gamble Health Limited | 2.56 Billion INR | 1.949% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -45.819% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -27.069% |
| Granules India Limited | 22.95 Billion INR | 89.06% |
| Aarti Drugs Limited | 11.5 Billion INR | 78.17% |
| Alkem Laboratories Limited | 48.6 Billion INR | 94.833% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 98.632% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -133.706% |
| Medicamen Biotech Limited | 940.36 Million INR | -167.053% |
| Unichem Laboratories Limited | 8.06 Billion INR | 68.878% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -285.0% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -769.558% |
| Valiant Laboratories Limited | 1.05 Billion INR | -137.302% |
| Orchid Pharma Limited | 3.84 Billion INR | 34.672% |
| Medico Remedies Limited | 438.24 Million INR | -473.031% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -9.689% |
| Ipca Laboratories Limited | 33.74 Billion INR | 92.558% |
| Brooks Laboratories Limited | 248.6 Million INR | -910.163% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -115.521% |
| Piramal Enterprises Limited | 560.47 Billion INR | 99.552% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 96.939% |
| NATCO Pharma Limited | 10.53 Billion INR | 76.156% |
| Suven Life Sciences Limited | 148.62 Million INR | -1589.718% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 15.557% |
| Strides Pharma Science Limited | 37.68 Billion INR | 93.335% |
| Indoco Remedies Limited | 10.34 Billion INR | 75.718% |
| Alpa Laboratories Limited | 307.12 Million INR | -717.68% |
| Lasa Supergenerics Limited | 541.92 Million INR | -363.399% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 35.491% |